Lindsay Fischer

Together, the associations stated that, like many other nurses following this case, they were hoping for a different outcome.

Two healthcare professionals with Cancer Treatment Centers of America® (CTCA) Phoenix, a comprehensive care and research center recently recognized with Magnet® distinction, discuss the importance of transparency in nursing satisfaction and engagement.

Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.

Findings from the KEYNOTE-091 trial showed that patients with non–small cell lung cancer who were treated with pembrolizumab following complete resection and chemotherapy had a 24% decreased risk of recurrence compared with a control arm.

Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.

Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy.

The PARP inhibitor demonstrated impressive overall survival benefit in patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.

New research shows that women are at an increased risk of developing an adverse event following cancer therapy compared with their male counterparts. This risk is particularly elevated among patients receiving immunotherapy.

The FDA has approved pembrolizumab to treat patients with endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, as determined by an FDA-approved test.

The ongoing FLORA-5 trial will assess whether the addition of oregovomab to a standard chemotherapy regimen will improve progression-free and overall survival in patients with advanced epithelial ovarian cancer.

The doublet regimen of relatlimab/nivolumab has been approved for adults with unresectable or metastatic melanoma.

La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.

Manufacturers will unblind trials evaluating bempegaldesleukin/nivolumab in melanoma in light of the final progression-free survival and overall response rates analyses.

Cabozantinib plus atezolizumab did not outperform sorafenib in improving overall survival in advanced hepatocellular carcinoma.

In this episode of “The Vitals,” Caitlin Benda, MBA, MS, RD, CSO, LDN, discusses important dietary considerations for patients with cancer.

The general population experienced nearly double the amount of anxiety and depression that patients with non–small cell lung cancer reported during the COVID-19 pandemic.

At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.

Nivolumab combined with chemotherapy is now approved in the resectable non–small cell lung cancer setting.

A new symptom-management guide designed by oncology nurses helps women with ovarian cancer feel more in control of their symptoms.

A comprehensive literature review underscores research gaps into optimal exercise regimens for childhood cancer survivors.

In this episode of “The Vitals,” Matt Iwaniec, PsyD, discusses the value of integrated behavioral health programs in cancer care.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

The FDA has initiated a priority review for neoadjuvant nivolumab plus chemotherapy to treat patients with resectable non–small cell lung cancer.

The FDA has approved pacritinib for patients with cytopenic myelofibrosis and severe thrombocytopenia.

Newly FDA-approved ciltacabtagene autoleucel was found to induce an objective response rate of 98% in patients with relapsed/refractory multiple myeloma.

Selinexor, an oral selective inhibitor of nuclear export, demonstrated promising efficacy in increasing progression-free survival among women with advanced endometrial cancer.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Compared with enzalutamide or abiraterone acetate tablets, olaparib was associated with decreased pain burden and better health-related quality of life in patients with castration-resistant prostate cancer.

An expert with Allegheny Health Network discusses the value of behavioral therapy and how access and stigma often play a role in preventing patients from receiving this form of care.

Weekly phone calls from RNs helped reduce the number of severe adverse events experienced by patients receiving ipilimumab for metastatic melanoma.